Jun 29, 2026 07:01AM

Jun 29, 2026 07:00AM

May 19, 2026 03:00PM

May 5, 2026 04:01PM

Mar 26, 2026 10:54AM

Mar 9, 2026 07:09AM

Mar 9, 2026 07:09AM Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Nov 5, 2025 04:01PM

Oct 16, 2025 09:57AM

Oct 16, 2025 07:00AM

Oct 16, 2025 07:00AM

Sep 9, 2025 06:49AM

Sep 8, 2025 07:00AM

Sep 8, 2025 07:00AM Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

Mar 5, 2025 07:02AM

Mar 5, 2025 07:00AM

Nov 11, 2024 07:51AM

Oct 4, 2024 10:10AM

Aug 8, 2024 04:01PM

Jun 12, 2024 07:00AM

Jun 12, 2024 07:00AM Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Feb 26, 2024 07:00AM

325,025 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All